Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies - Knisely, Anne; Ahmed, Jibran; Stephen, Bettzy; Piha‐Paul, Sarina A.; Karp, Daniel; Zarifa, Abdulrazzak; Fu, Siqing; Hong, David Sanghyun; Rodon Ahnert, Jordi; Yap, Timothy A.; Tsimberidou, Apostolia M.; Alshawa, Anas; et al. (Cancer, 2024)
Keywords: Agonists; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Cancer; Cervical cancer; Criteria; Disease control; Effectiveness; Endometrial cancer; Female; Genital Neoplasms, Female - drug therapy; Humans; immune checkpoint blockade; Immune checkpoint inhibitors; Immunoglobulin G; Immunotherapy; Malignancy; Monoclonal antibodies; Neoplasm Recurrence, Local - pathology; Ovarian cancer; Radiation therapy; Safety; Solid tumors; Survival; Targeted cancer therapy; Tumor necrosis factor; Tumors; Uterine cancer; Uterine Cervical Neoplasms - drug therapy; endometrial cancer; ovarian cancer; cervical cancer; immunotherapy; immune checkpoint blockade